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Reference methodof glomerular ﬁltration rate plays an important role in nephrological practice.
Iohexol is a referencemarker for glomerular ﬁltration rate determination. It is available and safe. The aim of this
study was to develop a simple, efﬁcient and easy to use analytical method for the quantiﬁcation of iohexol in
serum and urine by high performance liquid chromatography and to thoroughly validate this method.
Methods: The HPLC method was inspired from the method published by Krutzen. The e.noval software V2.0
(Arlenda, Liège, Belgium) was used to compute all validation results.
Results: The validation results indicate that the method will give accurate and reliable results for serum values
ranging from 12.95 to 1295 μg/ml and for urine values ranging from 86.0 to 4144 μg/ml. In routine practice,
iohexol concentrations found inplasma after injection range from40 to 600 μg/ml. The expected urinary values
aremuchwider. One should not hesitate to dilute urine samples toﬁtwith the validated rangeover 5000 μg/ml.
Conclusion: This is the ﬁrst time that a reference method for the determination of GFR is validated with such a
rigorous and thorough protocol. Contrary to other GFR markers, iohexol is now strongly validated from an
analytical point of view.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Determination of glomerular ﬁltration rate (GFR) plays an
important role in daily nephrological practice. Indeed, its determina-
tion is crucial to diagnose chronic kidney diseases (CKD) or evaluate
risks of developing CKD.
Several steps are required in order to achieve a reliable GFR. The ﬁrst
point is the selection of the GFR marker, the substance that will be
monitored in order to determine the ﬁltration rate. The ideal features of
the substance to bemonitored in order to evaluate the GFR are to appear
endogenously in the plasma at constant rate, be freely ﬁltered by the
glomerulus without renal tubule absorption or secretion and without
extra-renal elimination [1]. This ideal substance does exist but is
exogenous: inulin (a fructose polymer). The renal clearance of inulin is
thus the “gold standard” for the GFR measurement. However, its appli-
cation is expensive and tedious [2]. Moreover, inulin is not always easily
available on the market. The most used marker in clinical practice is
endogenous and is serumcreatinine. However, it does not comply to all ofentre Hospitalier Universitaire
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ll rights reserved.these last features [3] and it is indeed a poormarker for GFR, especially in
speciﬁc population like obese, anorectic and transplanted patients [4,5].
In these speciﬁc patients and in clinical nephrological studies, a precise
GFR measurement is needed. As inulin clearance measurement is not
easy, other methods have been developed as isotopic methods such as
51Cr-ethylenediaminetetra-acetic acid (EDTA) (although not available in
the United States) or 99Tc-diethylenetriaminepentaacetic acid (DTPA)
[6,7]. However these markers require special handling, radiation
exposure and are costly. Contrast agents like iothalamate or iohexol (N,
N'-bis (2,3-dihydroxypropyl)-5-(N-2,3-dihydroxypropyl)acetamido)-
2,4,6-triiodoisophtalamide) are also available and have the features of
the ideal marker together with being easily available and safe. Thus
iohexol clearance is replacing inulin clearance as a marker of choice for
GFR [2,8–10].
Once the ideal marker has been chosen, the next step is the
development of an accurate quantitative analytical method to obtain
reliable concentration values of thismarker in the serum. The objective
of any quantitative analytical method is to obtain results that are close
enough to the unknown true value of analyte under investigation in
the samples analyzed. One way to demonstrate that the analytical
method will provide reliable results is to perform method validation.
The objective ofmethod validation is thus to give guarantees thatmost
of the results that will be generated during routine use of this method
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fails to give this guarantee then decision based on the results obtained
by this method will be unreliable and may cause errors in diagnostics:
declaring a healthy patient as ill and vice versa.
Various chromatographicmethods have been described for iohexol
determination, mainly in serum [11–13]. However, one should notice
that thesemethodshavebeenpoorly analytically validated. Evenmore,
validation for the determination in urinematrix with thesemethods is
clearly lacking.
Thus, the aim of this paper is ﬁrst to develop a simple, efﬁcient and
easy touse routinelyanalyticalmethod for thequantiﬁcationof iohexol in
serum and urine by high performance liquid chromatography (HPLC)
inspired from the method published by Krutzen et al. [12]. Secondly, a
thorough validation of this method is performed, which will provide
guarantees about the accuracy and thus the reliability of the results that
will beobtainedby thismethodduring futureday todayanalysis. Inorder
to attainmaximumguarantees risk toobtain results outsidepre-speciﬁed
acceptance limits is provided as well as the measurement uncertainty.
2. Materials and methods
2.1. Terminology
Before going on with the main aims of this paper it is important to deﬁne several
crucial terms, which are sources of confusion depending on the environment in, which
one works or, which are not usually well known.
▪ Accuracy, as deﬁned in ISO documents or in documents ICH Q2R1 section
terminology, is “the closeness of agreement between the value, which is accepted
either as a conventional true value or an accepted reference value and the value
found.” [14–23]. It therefore refers to total measurement error.
Trueness refers to “the closeness of agreement between the average value obtained
from a large series of test results and an accepted reference value” [15,16,19]. This
concept is therefore related to the systematic error of a measurement process.
▪ Precision refers to “the closeness of agreement (degree of scatter) between a series
of measurements obtained from multiple sampling of the same homogeneous
sample under the prescribed conditions.” [14–23].This is related to the random
error of a measurement process.
As can be understood from these deﬁnitions, the main point is that accuracy is the
simultaneous combination of both systematic and random errors, i.e. total error [15,16,19].
▪ Uncertainty of measurement is deﬁned as “a parameter associated with the result
of a measurement, that characterizes the dispersion of the values that could
reasonably be attributed to the measurand” [19–21].
▪ β-expectation tolerance intervals are intervals that contain a proportion β of the
individual values, such as results, of the population under investigation (e.g. 0.95).
These intervals allow to describe the entire population and are less known than
conﬁdence intervals [22]. These intervals are called “β-expectation tolerance
intervals” (also known as “mean coverage tolerance intervals” or “prediction
intervals”). If β=0.95, this means that on average, 95% of the future individual
values (results) of the population are included in the interval [L; U] [23].Fig. 1. Chromatogram of a serum2.2. Chemicals
Iohexol (Omnipaque ™) was purchased from Amersham Health (South Plainﬁeld,
NJ, USA). Perchloric and orthophosphoric acid were both reagent grade and were
purchased from Merck (Darmstadt, Germany) and HPLC grade acetonitrile from Lab-
Scan (Dublin, Ireland).
Ultrapure distilled and deionizedwaterwas prepared in-house andﬁltered prior to use.
2.3. HPLC equipment and mobile phase
The HPLC equipment consisted of a Hewlett–Packard (HP) 1100 Model (Agilent
Technologies, Palo Alto, CA, USA). The Lichrospher analytical column (Merck;
250×4 mm I.D.; particle size: 5 μM) was packed with C18 material.
Themobile phase consisted of a mixture of distilled water and acetonitrile (95:5: v/v)
adjusted to pH 3.0 with orthophosphoric acid. The separationwas performed isocratically
with a ﬂow rate of 1.0ml/min. Typical HPLC operating pressurewas approximately 70 bars
at a thermostatised column oven temperature of 40 °C.
An injection volume of 20 μl for serum and urine samples was accomplished using
the HP 1100 autosampler. Detection was achieved with the HP 1100 DAD detector at an
absorbance wavelength of 254 nm.
2.4. Standard and control preparation
Standards stock solutions of iohexol (520 mg/ml in deionized water) were prepared
and stored at 4 °C. Working serum and urine standards as well as control samples were
prepared by dilution of the stock solutions with adequate volumes of blank human
serum and urine.
2.5. Calculations
The e.noval software V2.0 (Arlenda, Liège, Belgium) was used to compute all
validation results and build the accuracy proﬁles.
2.6. Serum and urine samples preparation
To deproteinize the serum matrix, 100 μl of serum were treated with 100 μl of 5%
perchloric acid. The tubes were then spun at 11,000 g at 4 °C during 10 min. The
supernatant was directly transferred to glass HPLC vials.
Fifty microlitres of urine were directly diluted in the glass autosampler vial with
1 ml of deionised water and vortex mixed for 10 s.
3. Results
3.1. Method optimization
The method previously published by Krutzen et al. [12], was
modiﬁed by ﬁrst, adjusting the pH of the mobile phase from 2.5 to 3.0,
then the volume of perchloric acid necessary to precipitate the serum
proteins was reduced from 5 volumes to 1 volume and ﬁnally the ﬂow
rate reduced from 1.5 to 1 ml/min. These conditions provided good
peak shape. The iohexol isomers eluted at 4.3 and 4.7 min (Fig. 1).130 μg/ml iohexol calibrator.
Fig. 2. Accuracy proﬁles, using a for calibration curve a weighted (1/X) linear regression
model for serumandurine. Acceptance limits (….),β-expectations tolerance limits (----)
and relative bias (___).
Table 1
Method validation for iohexol determination in serum and urine.
Validation criterion Serum Urine




Calibration range (7 points):
6.47–1295 μg/ml
Calibration range (7 points):
52.0–4144 μg/ml
Trueness Concentration Relative bias Concentration Relative bias
Level 1 8.63 μg/ml −3.4% 86 μg/ml 8.4%
Level 2 12.95 μg/ml −1.3% 518 μg/ml 3.7%
Level 3 64.75 μg/ml 0.7% 1036 μg/ml 1.9%
Level 4 259 μg/ml 2.0% 4144 μg/ml 4.0%
Level 5 518 μg/ml 6.2%





Level 1 15.0/17.0 0.8/3.5
Level 2 4.2/4.2 0.8/4.8
Level 3 4.4/4.4 4.2/4.7
Level 4 3.1/3.3 2.9/4.1
Level 5 2.1/2.1
Level 6 2.4/2.7
Accuracy β-expectation lower and
upper tolerance limits of the
relative error (%)
β-expectation lower and
upper tolerance limits in
relative error (%)
Level 1 −47.8; 41.1 −8.0; 24.7
Level 2 −11.6; 9.1 −19.0; 26.4
Level 3 −10.1; 11.6 −10.1; 13.8
Level 4 −6.4; 10.5 −8.2; 16.1
Level 5 1.1; 11.4
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3.2.1. Selectivity
The absence of interfering endogenous components of urine and
serum at the retention time of iohexol was demonstrated after
analysis of serum and urine spiked with iohexol and blank samples
from six different sources of the same matrices (data not shown).
3.2.2. Response function
The response function is, within a certain range, the relationship
between the response observed and the concentration of the analyte
in the sample [24]. Thus, the selection of the calibration curve for the
quantiﬁcation of iohexol in the two matrices should be the ﬁt for
purpose response function [25]. To determine the most adequate one
for our goal, different calibration models have been evaluated. As
iohexol is not naturally present in serum or urine, the calibration
curves were prepared by spiking a pool of serum and of urine in order
to reach 7 concentration levels ranging from 6.47 to 1295 μg/ml for
serum and from 52.0 to 4144 μg/ml for urine, respectively. Each
calibration point was analyzed in duplicate on three consecutive days.
Independent validation standards were also prepared by proceed-
ing in the same way: for serum, 6 validation standards ranging from8.63 to 1295 μg/ml were analyzed in triplicate on three consecutive
days and for urine, 4 validation standards ranging from 86.0 to
4144 μg/ml were analyzed in triplicate on three consecutive days.
From the results obtained, the concentrations of the validation
standards were back-calculated to determine the mean relative bias,
the standard deviation for intermediate precision and ﬁnally the
upper and lower β-expectation tolerance limits at 95% level [16,26].
Different accuracy proﬁle were thus plotted to select the most
convenient regression model for the analytical method. The accep-
tance limits were set at ±30% as recommended [26]. As shown in
Fig. 2, the best response function for serum as well as for urine was
achieved with the weighted (1/X) linear regression. The response
functions obtained by applying these regression models are presented
in Table 1.
3.2.3. Trueness
Trueness, expressed in terms of relative bias (%), was calculated
from the validation standards [16,24]. As can been seen in Table 1,
trueness was acceptable (relative bias smaller than 10%) for both
matrices serum and urine.
3.2.4. Precision
The precision of the method was determined by computing the
Relative Standard Deviations (RSDs) for repeatability and time-
different intermediate precision at each concentration level of the
validation standards [16,24,26]. For serum and urine, the precision at
each concentration level of the validation standards did not exceed
15% (Table 1).
3.2.5. Accuracy, LOQ and LOD
Accuracy takes into account the total error (sum of the systematic
and random errors) of the test results [16,24,26]. As shown in Table 1,
the relative upper and lower β-expectation tolerance limits (%) did not
exceed the acceptance limits (±30%) for each concentration level and
for both matrices.
Fig. 3. Linearity proﬁles for serum and urine. Identity line (___) when Y=X, upper and
lower acceptance limits in absolute values (….), and upper and lower β-expectation
tolerance limits (----).
Fig. 4. Risk proﬁles for serum and urine. The maximum tolerated risk is set at 5%.
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between 12.95 and 1295 μg/ml for serum samples, and between 86.0
and 4144 μg/ml for urine.
The limit of detection (smallest quantity of the analyte than can
be detected in the sample, but not quantiﬁed) was evaluated at
3.08 μg/ml for serum and 26.06 μg/ml for urine. The limits of
quantiﬁcation, obtained by calculating the smallest and the highest
concentration beyond, which the β-expectation limits go outside the
acceptance limits were 10.76 and 1295 μg/ml for the lowest and
highest limits for serum, respectively. For urine, they were at 86.0 and
4144 μg/ml.
3.2.6. Linearity of the results
To evaluate the linearity of the method results, a linear regression
line was ﬁtted on the back-calculated concentrations of the validation
standards [16,24,26]. The equations obtained and the coefﬁcients of
determination are shown in Table 1. The linearity was demonstrated
using the β-expectation tolerance interval approach, as the absolute
upper and lower β-expectation tolerance limits were included inside
the absolute acceptance limits, irrespective of the concentrations
studied (Fig. 3).3.3. Risk assessment
The effective risk of having a future measurement falling outside
the speciﬁed acceptance limits of ±30% total error by using the β-
expectation tolerance intervals obtained with the selected regression
models was also evaluated. This risk is calculated as the sum of the
proportion of results lying above the upper and under the lower
acceptance limits for each concentration level tested [27]. The
maximum risk tolerated was set at 5%, it means that in routine
practice, we do not accept no more than 5% of our samples to fall
outside the ±30% acceptance limits, which is acceptable in clinical
biology. Fig. 4 shows the risk proﬁle associated at each level studied
for both matrices. None of the levels included in the validated range
presented a risk higher than 5% for serum. However for the lowest
concentration tested (8.63 μg/ml) where the method is not anymore
valid the effective risk to obtain a result out of the acceptance limits is
of about 22%. For urine samples, the risk associated to all the
concentration levels tested is well under the maximum risk of 5%
reaching its maximum value 3.7% for the 518 μg/ml level. The
integration of the risk proﬁle in the validation process allows us to
determine how far our method will be reliable for its routine
utilisation by knowing the effective risk of obtaining out of speciﬁca-
tion results during the future routine use of the method.
Table 2
Estimates of measurement uncertainties related to iohexol measurement in serum and urine, at each concentration level investigated.
SERUM Concentration (μg/ml) Uncertainty of the bias (μg/ml) Uncertainty (μg/ml) Expanded uncertainty (μg/ml) Relative uncertainty (%)
Level 1 8.63 0.59 1.58 3.16 36.7
Level 2 12.95 0.18 0.58 1.16 8.9
Level 3 64.75 0.96 3.02 6.05 9.3
Level 4 259.0 3.19 9.22 18.44 7.1
Level 5 518.0 3.62 11.44 22.89 4.4
Level 6 1295 13.33 37.10 74.20 5.7
URINE Concentration (μg/ml) Uncertainty of the bias (μg/ml) Uncertainty (μg/ml) Expanded uncertainty (μg/ml) Relative uncertainty (%)
Level 1 86.00 1.71 3.47 6.94 8.1
Level 2 518.0 14.07 28.35 56.70 10.9
Level 3 1036 18.65 51.72 103.4 9.9
Level 4 4144 78.55 185.6 371.1 8.9
84 E. Cavalier et al. / Clinica Chimica Acta 396 (2008) 80–853.4. Uncertainty assessment
The uncertainty characterizes the dispersion of the values that
could reasonably be attributed to the measurand [28]. Several
uncertainty results were generated and are presented in Table 2: the
uncertainty of bias of the method at each concentration level of the
validation standard, the uncertainty, which combines the uncertainty
of the bias with the uncertainty of the method obtained during the
validation step, i.e. the intermediate precision standard deviation, and
the expanded uncertainty, which equals to the uncertainty multiplied
by a coverage factor k=2, representing an interval around the results
where the unknown true value can be observed with a conﬁdence
level of 95% [28]. In addition, the relative expanded uncertainties (%)
sor serum and urine obtained by dividing the corresponding
expanded uncertainties with the corresponding introduced concen-
trations (Table 2) are not higher than 10%, which means that with a
conﬁdence level of 95%, the unknown true value is located at a
maximum of ±10% around the measured result. Only for the ﬁrst
concentration level of iohexol in serum (8.63 μg/ml) is the relative
expended uncertainty extremely high, about 36%.
4. Discussion
A simple HPLC/UVmethod for iohexol determination in serum and
urine was successfully analytically validated. This is the ﬁrst time that
a reference method for the determination of GFR is validated with
such a rigorous and thorough protocol. Contrary to other GFRmarkers,
iohexol is now strongly validated from an analytical point of view and
the method is now ready for its clinical application. Moreover, iohexol
determination in urine has been poorly studied. Now, on particular
conditions and especially in patients with ascite or interstitial oedema,
the accurate measure of the urinary clearance is of importance and
better than the plasma clearance [29]. Moreover, the reproducibility of
GFR measurement is relatively high (around 10%). This reproducibility
could certainly be improved if the analytical performance of the
marker used for determination (inulin, isotopic or contrast agent) was
improved [30,31].
The validation results indicate that the method will give accurate
and reliable results for serumvalues ranging from 12.95 to 1295 μg/ml
and for urine values ranging from 86.0 to 4144 μg/ml. In routine
practice, iohexol concentrations found in plasma after injection of 5ml
of Omnipaque® (520 μg/ml) usually range from 40 to 600 μg/ml,
related to the renal status of the patient and the delay between
injection and sampling. The expected urinary values are much wider,
depending on the hydratation and the renal function of the patients.
As the response of the detector is no linear any more over 4144 μg/ml,
one should not hesitate to dilute urine samples to ﬁt with the
validated range over 4144 μg/ml. Indeed, urine values usually found in
our experience can range from 700 μg/ml to more than 12000 μg/ml.
These values are much higher than what had previously been
validated for urinary iohexol (10–50 μg/ml) [32].The original validation approach applied, using accuracy proﬁles
based on β-expectation tolerance intervals for the total measurement
error, allowed to evaluate the capability of the method to give ﬁt for
purpose results. The concept of accuracy proﬁle was also used to select
the most appropriate regression model for calibration, to determine
the limit of quantiﬁcation (LOQ) and the range over, which themethod
can be considered as valid.
Moreover, the risk with respect to the future use of the validated
method was estimated and it was demonstrated to be lower than 5%
over the whole validated range of concentration for both matrices.
Finally, the measurement uncertainties were estimated, allowing
correct interpretation and comparison of the results.
From an analytical point of view, we have shown that iohexol
determination by HPLC/UV is accurate to meet the clinical goals in GFR
measurement.
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